申请人:HOFFMANN-LA ROCHE INC.
公开号:US20150376166A1
公开(公告)日:2015-12-31
This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
本申请公开了按通用式(I)定义的化合物,其中所有变量如本文所述,可抑制BTK。本文所披露的化合物有助于调节BTK的活性,治疗与过度BTK活性有关的疾病。这些化合物还有助于治疗与异常B细胞增殖有关的炎症和自身免疫性疾病,如类风湿性关节炎。还披露了含有通式I的化合物和至少一种载体、稀释剂或赋形剂的组合物。